Conference Program
 
Antibody Biology & Engineering
From Basic Mechanisms To Antibody-Based Therapeutics
March 7-12, 2010
Ventura Beach Marriott
Ventura, CA
Chairs:
E. Sally Ward & Davinder Gill

Vice Chair:
Derry Roopenian
Application Deadline
Applications for this meeting must be submitted by February 14, 2010. Please apply early, as some meetings become oversubscribed (full) before this deadline. If the meeting is oversubscribed, it will be stated here. Applications will still be accepted for oversubscribed meetings. However, they will only be considered by the Conference Chair if more seats become available due to cancellations.

Antibodies play a fundamental role in protection from infectious organisms and in promoting autoimmunity. Because of their remarkable molecular specificity antibody-based therapeutics are widely regarded to be a promising means to target a myriad of diseases. The success of antibody-based drugs has resulted in major part from significant developments in antibody engineering approaches. However, the full realization of antibody-based therapeutics requires a deeper understanding the biological pathways that regulate B cells and the mechanisms of antibody function and homeostasis in vivo.

The emphasis of this meeting will be two-fold: (1) the basic biology of B cells leading to their production of antibodies: (2) the exploitation of antibodies for therapeutic purposes. Leading researchers from diverse areas will present their most recent findings on topics covering B-cell biology, tolerance, antibody repertoires, molecular functions of antibodies, structure/function relationships, imaging, and antibody based therapeutics. The meeting will be the first GRC focusing on this interdisciplinary area and is intended to help unify thoughts in the areas of basic B cell/antibody biology together with the engineering of antibodies, which could set the stage for future advancement in these areas.

SUNDAY
4:00 pm - 8:00 pmArrival and Check-in (Office Closed 6:00 pm - 7:45 pm)
6:00 pmDinner
7:30 pm - 7:40 pmWelcome / Introductory Comments by GRC Site Staff
7:40 pm - 9:30 pmKEYNOTE PRESENTATIONS: B CELL BIOLOGY
Discussion Leader: Don Capra (Oklahoma Medical Research Foundation)
7:40 pm - 7:50 pm Don Capra (Oklahoma Medical Research Foundation)
"Opening remarks"
7:50 pm - 8:30 pm Klaus Rajewsky (Harvard Medical School)
"Antibodies as determinants of B cell development, maintenance and response"
8:30 pm - 8:40 pm Discussion
8:40 pm - 9:20 pm Jason Cyster (University of California-San Francisco)
"Lymphocyte migration and the humoral immune response"
9:20 pm - 9:30 pm Discussion
MONDAY
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmANTIBODY REPERTOIRES AND DIVERSIFICATION MECHANISMS
Discussion Leader: Fred Alt (Harvard Medical School)
9:00 am - 9:15 am Fred Alt (Harvard Medical School)
"Opening remarks"
9:15 am - 9:35 am Michael Neuberger (MRC Laboratory of Molecular Biology, Cambridge)
"DNA deamination in the generation of high affinity antibodies"
9:35 am - 9:45 am Discussion
9:45 am - 9:55 am Short talk (selected from abstracts)
9:55 am - 10:00 am Discussion
10:00 am Coffee Break / Group Photo
10:30 am - 10:50 am Nina Papavasiliou (Rockefeller University)
"New approaches to the identification of AID cofactors"
10:50 am - 11:00 am Discussion
11:00 am - 11:20 am Patrick Wilson (University of Chicago)
"Plasmablasts: the workhorses of human B cell memory"
11:20 am - 11:30 am Discussion
11:30 am - 11:50 am James Marks (University of California - San Francisco)
11:50 am - 12:00 pm Discussion
12:00 pm - 12:15 pm Marie-Paule Lefranc (Université Montpellier)
"Standardized sequence and structure analysis of antibodies using IMGT®"
12:15 pm - 12:30 pm Discussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 6:00 pmPoster Session I
6:00 pmDinner
7:30 pm - 9:30 pmMOLECULAR RECOGNITION BY ANTIBODIES AND FcγRs
Discussion Leader: Dennis Burton (The Scripps Research Institute)
7:30 pm - 7:45 pm Dennis Burton (The Scripps Research Institute)
"Opening remarks"
7:45 pm - 8:05 pm Ian Wilson (The Scripps Research Institute)
"Antibody recognition of pandemic influenza viruses"
8:05 pm - 8:15 pm Discussion
8:15 pm - 8:35 pm Dinakar Salunke (National Institute of Immunology, New Delhi)
"Revisiting tenets of specificity and recognition in the humoral immune response"
8:35 pm - 8:45 pm Discussion
8:45 pm - 9:05 pm Mark Hogarth (Burnet Institute, Melbourne)
"The interplay between Fc receptor organization and IgA or IgG binding in leukocyte activation and inhibition: lessons for future therapeutics?"
9:05 pm - 9:10 pm Discussion
9:10 pm - 9:25 pm Wayne Marasco (Harvard Medical School)
"The basis and bias of human anti-influenza antibody responses"
9:25 pm - 9:30 pm Discussion
TUESDAY
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmFUNCTIONAL EFFECTS OF FcγRs AND COMPLEMENT
Discussion Leader: Jenny Woof (University of Dundee Medical School)
9:00 am - 9:15 am Jenny Woof (University of Dundee Medical School)
"Opening remarks"
9:15 am - 9:35 am John Cambier (National Jewish Health, Denver)
"Multiple access points to the SHIP/Dok signaling pathways and their functional reports"
9:35 am - 9:45 am Discussion
9:45 am - 9:55 am Short talk (selected from abstracts)
9:55 am - 10:00 am Discussion
10:00 am Coffee Break
10:30 am - 10:50 am Raphael Clynes (Columbia University)
"Fc receptors and modulation of adaptive immunity"
10:50 am - 11:00 am Discussion
11:00 am - 11:20 am Jeanette Leusen (University Medical Center Utrecht)
"Biology of Fc receptors: impact on therapeutic antibodies"
11:20 am - 11:30 am Discussion
11:30 am - 11:50 am Louis Weiner (Georgetown University Medical Center)
"Antibody-initiated cancer immunotherapy"
11:50 am - 12:00 pm Discussion
12:00 pm - 12:10 pm Short talk (selected from abstracts)
12:10 pm - 12:30 pm Discussion
12:30 pmLunch
1:30 pm - 6:00 pmFree Time
6:00 pmDinner
7:30 pm - 9:30 pmFcRn AND IgG DYNAMICS
Discussion Leader: John Desjarlais (Xencor, Inc.)
7:30 pm - 7:45 pm John Desjarlais (Xencor, Inc.)
"Opening remarks"
7:45 pm - 8:05 pm Richard Blumberg (Harvard University)
"Role of FcRn in antigen presentation by dendritic cells"
8:05 pm - 8:15 pm Discussion
8:15 pm - 8:35 pm Inger Sandlie (University of Oslo)
"The half-lives of human IgG subclasses"
8:35 pm - 8:45 pm Discussion
8:45 pm - 9:05 pm William Dall'Acqua (MedImmune, LLC)
"Modulating the pharmacokinetic properties of therapeutic IgGs via Fc engineering: the YTE platform"
9:05 pm - 9:30 pm Discussion
WEDNESDAY
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmIMAGING OF ANTIBODIES AND ANTIBODY-RELATED PROCESSES
Discussion Leader: Ira Mellman (Genentech, Inc.)
9:00 am - 9:15 am Ira Mellman (Genentech, Inc.)
"Opening remarks"
9:15 am - 9:35 am Anna Wu (University of California - Los Angeles)
"ImmunoPET- in vivo immunohistochemistry?"
9:35 am - 9:45 am Discussion
9:45 am - 9:55 am Short talk (selected from abstracts)
9:55 am - 10:00 am Discussion
10:00 am Coffee Break
10:30 am - 10:50 am Michael Carroll (Harvard Medical School)
"B cell acquisition of lymph-borne antigens within LNs"
10:50 am - 11:00 am Discussion
11:00 am - 11:20 am Raimund Ober (University of Texas at Dallas)
"Imaging antibody trafficking in cells at the single molecule level in 3D"
11:20 am - 11:30 am Discussion
11:30 am - 11:50 am Diane Lidke (University of New Mexico)
"Correlating FcεRI signaling with receptor dynamics using single quantum dot tracking"
11:50 am - 12:00 pm Discussion
12:00 pm - 12:10 pm Short talk (selected from abstracts)
12:10 pm - 12:30 pm Discussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 6:00 pmPoster Session II
6:00 pmDinner
7:00 pm - 7:30 pmBusiness Meeting
(Nominations for the next Vice Chair; Fill out Conference Evaluation Forms; Discuss future Site & Scheduling preferences; Election of the next Vice Chair)
7:30 pm - 9:30 pmB CELL TOLERANCE
Discussion Leader: John Cambier (National Jewish Health, Denver)
7:30 pm - 7:45 pm John Cambier (National Jewish Health, Denver)
"Opening remarks"
7:45 pm - 8:05 pm David Nemazee (The Scripps Research Institute)
"Self/nonself discrimination in mouse B cells"
8:05 pm - 8:15 pm Discussion
8:15 pm - 8:35 pm Robert Rickert (Burnham Institute)
"Signaling pathways regulating B cell tolerance and autoantibody production"
8:35 pm - 8:45 pm Discussion
8:45 pm - 9:05 pm Eric Meffre (Yale University)
"Human B cell tolerance checkpoints in health and autoimmune diseases"
9:05 pm - 9:30 pm Discussion
THURSDAY
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmANTIBODY FRAGMENTS AND NOVEL PROTEIN SCAFFOLDS
Discussion Leader: Paul Carter (VLST Corporation)
9:00 am - 9:15 am Paul Carter (VLST Corporation)
"Opening remarks"
9:15 am - 9:35 am Andreas Plückthun (University of Zürich)
"Protein engineering solutions to tumor targeting"
9:35 am - 9:45 am Discussion
9:45 am - 9:55 am Short talk (selected from abstracts)
9:55 am - 10:00 am Discussion
10:00 am Coffee Break
10:30 am - 10:50 am Dane Wittrup (Massachusetts Institute of Technology)
"Efficient EGFR downregulation with heterodimers of Fn3 scaffold-based binding domains"
10:50 am - 11:00 am Discussion
11:00 am - 11:20 am Dominik Ruettinger (Micromet, Inc.)
"Cancer therapy with T cell engaging BiTE antibodies"
11:20 am - 11:30 am Discussion
11:30 am - 12:00 pm Kerry Chester / Richard Begent (University College London)
"Recombinant antibodies and fusion proteins for cancer imaging and therapy"
12:00 pm - 12:15 pm Discussion
12:15 pm - 12:25 pm Short talk (selected from abstracts)
12:25 pm - 12:30 pm Discussion
12:30 pmLunch
1:30 pm - 6:00 pmFree Time
6:00 pmDinner
7:30 pm - 9:30 pmTHERAPEUTIC ANTIBODIES
Discussion Leader: Andrew Chan (Genentech, Inc.)
7:30 pm - 7:45 pm Andrew Chan (Genentech, Inc.)
"Opening remarks"
7:45 pm - 8:05 pm Philip Thorpe (University of Texas Southwestern Medical Center)
"Targeting phosphatidylserine in the tumor microenvironment to destroy tumor blood vessels and induce tumor immunity"
8:05 pm - 8:15 pm Discussion
8:15 pm - 8:35 pm TBA
8:35 pm - 8:45 pm Discussion
8:45 pm - 9:05 pm Gene Kinney (Janssen Alzheimer Immunotherapy R&D)
"The use of anti-Aβ immunotherapy for the treatment of Alzheimer's disease"
9:05 pm - 9:30 pm Discussion
FRIDAY
7:30 am - 8:30 amBreakfast
9:00 amDepart
Funding for this conference was made possible [in part] by 1R13AI085574-01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Last Updated: February 2, 2010